Advertisement
Journal Home
Search for

Volume 194, Issue 1, Pages 116-124 (September 2007)


View previous. 11 of 48 View next.

C-terminal apolipoprotein E-derived peptide, Ep1.B, displays anti-atherogenic activity

Leila Bockschab, Beverly J. Riderb, Tracey Stephensb, Erbin Daia, Liying Liua, Hong Diaoa, Kasinath Viswanathanab, Ganesh Munuswamy-Ramanujamabd, Bhagirath Singhbe, Alexandra LucasabcdCorresponding Author Informationemail addressemail address

Received 6 September 2005; received in revised form 5 September 2006; accepted 6 October 2006. published online 26 November 2006.

Abstract 

Objective

Apolipoprotein E (ApoE) is a lipid transport protein with expanded functions in cellular responses to tissue injury, immune regulation and cell growth. ApoE directs vascular changes that contribute to arterial protection as evidenced by the fact that isoforms of ApoE and ApoE deficiency correlate closely with accelerated plaque growth. The N-terminus of the ApoE protein has well-characterized functions, displaying lipid-binding and anti-atherogenic activity, whereas the function of the C-terminus is only partially defined. We have assessed the effects of a 14 amino acid C-terminal ApoE peptide, termed Ep1.B (239–252), on intimal neoplasia in animal models. This peptide is a fragment of a naturally processed peptide (236–252) of murine ApoE.

Methods and results

Ep1.B injection reduced neointimal hyperplasia after vascular surgery in rats and mice. When given during early plaque progression in ApoE-deficient mice, Ep1.B injections also prevented plaque growth. Treatment with Ep1.B did not, however, reduce established plaque growth in older mice. Peptides with alanine substitution of amino acid 249, Ep1.N, and with complete sequence reversal, Ep1.R, did not consistently inhibit plaque growth.

Conclusion

A naturally processed C-terminal ApoE peptide, Ep1.B, has anti-atherogenic activity indicating a role for this naturally metabolized peptide in vascular wound healing and lipid homeostasis.

a Vascular Biology Group, Robarts’ Research Institute, Canada

b Department of Microbiology and Immunology, Canada

c Division of Cardiology, Department of Medicine, London Health Sciences Center, University of Western Ontario, London, Ont., Canada

d Division of Cardiovascular Medicine, Vascular Biology Research Group, University of Florida, Gainesville, FL, USA

e Institute of Infection and Immunity, Canadian Institutes of Health Research, London, Ont., Canada

Corresponding Author InformationCorresponding author at: Department of Cardiovascular Medicine, University of Florida, 1600 SW Archer Road, Box 100277, Gainesville, FL 32610-0277, USA. Tel.: +1 352 672 2301; fax: +1 352 846 0433.

PII: S0021-9150(06)00609-5

doi:10.1016/j.atherosclerosis.2006.10.014


View previous. 11 of 48 View next.

Advertisement